CLINICAL_TRIALS
trial_result
· 2025-08-24
Clinical Trial Update: Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia [Phase 3]
Summary
Phase 3 extension study of pimavanserin as adjunctive treatment for schizophrenia was terminated; results from the study were posted on 2025-08-24.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: ACADIA Pharmaceuticals Inc. | Conditions: Schizophrenia | Phase 3 | Status: TERMINATED | Results posted: 2025-08-24